Literature DB >> 15980343

Antibacterial properties of some cyclic organobismuth(III) compounds.

Toshiaki Kotani1, Daisuke Nagai, Kensuke Asahi, Hitomi Suzuki, Fumiaki Yamao, Nobumasa Kataoka, Tatsuo Yagura.   

Abstract

Bismuth compounds are known for their low levels of toxicity in mammals, and various types of bismuth salts have been used to treat medical disorders. As part of our program to probe this aspect of bismuth chemistry, cyclic organobismuth compounds 1 to 8 bearing a nitrogen or sulfur atom as an additional ring member have been synthesized, and their antimicrobial activities against five standard strains of gram-negative and gram-positive bacteria were assessed. The eight-membered-ring compounds, compounds 1 to 3, exhibited MICs of less than 0.5 microg/ml against Staphylococcus aureus and were more active than the six-membered ones, compounds 5 to 8 (MICs, 4.0 to 16 microg/ml). The gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis, and Enterococcus faecalis) were more susceptible to both types of ring compounds than the gram-negative ones (Escherichia coli and Pseudomonas aeruginosa). Treatment with polymyxin B nonapeptide increased the susceptibility of E. coli to cyclic organobismuth compounds, indicating the low permeability of the outer membrane of gram-negative bacteria to the compounds. Compound 1 also had activity against methicillin-resistant S. aureus, which had an MIC for 90% of the hospital stock strains of 1.25 microg/ml. The killing curves for S. aureus treated with compound 1 or 3 revealed a static effect at a low dose (2x the MIC). However, when S. aureus was treated with 10x the MIC of compound 1 or 3, there was an approximately 3-log reduction in the viable cell number after 48 h of treatment. Electron microscopic inspection demonstrated a considerable increase in the size of S. aureus and the proportion of cells undergoing cell division after treatment with compound 1 at 0.5x the MIC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980343      PMCID: PMC1168658          DOI: 10.1128/AAC.49.7.2729-2734.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Bismuth compounds and preparations with biological or medicinal relevance.

Authors:  G G Briand; N Burford
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Enhancement of bismuth antibacterial activity with lipophilic thiol chelators.

Authors:  P Domenico; R J Salo; S G Novick; P E Schoch; K Van Horn; B A Cunha
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Activities of bismuth thiols against staphylococci and staphylococcal biofilms.

Authors:  P Domenico; L Baldassarri; P E Schoch; K Kaehler; M Sasatsu; B A Cunha
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 4.  Bismuth subsalicylate: history, chemistry, and safety.

Authors:  D W Bierer
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

5.  Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide.

Authors:  M Vaara; T Vaara
Journal:  Nature       Date:  1983 Jun 9-15       Impact factor: 49.962

6.  Antimicrobial activities of synthetic bismuth compounds against Clostridium difficile.

Authors:  D E Mahony; S Lim-Morrison; L Bryden; G Faulkner; P S Hoffman; L Agocs; G G Briand; N Burford; H Maguire
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci.

Authors:  Joan C Fung-Tomc; Junius Clark; Beatrice Minassian; Michael Pucci; Yuan-Hwang Tsai; Elizabeth Gradelski; Lucinda Lamb; Ivette Medina; Elizabeth Huczko; Benjamin Kolek; Susan Chaniewski; Cheryl Ferraro; Thomas Washo; Daniel P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action.

Authors:  M Vaara; P Viljanen; T Vaara; P H Mäkelä
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

9.  In vitro antibacterial activity of bismuth subsalicylate.

Authors:  N A Cornick; M Silva; S L Gorbach
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb
  9 in total
  4 in total

1.  Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells.

Authors:  Yifan Hong; Yau-Tsz Lai; Godfrey Chi-Fung Chan; Hongzhe Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

2.  6-Cyclo-hexyl-6,7-dihydro-dibenzo[c,f][1,5]aza-bis-mocin-12(5H)-yl(N→Bi) trifluoro-methane-sulfonate.

Authors:  Nianyuan Tan; Xiaowen Zhang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-01-22

Review 3.  Current and potential applications of bismuth-based drugs.

Authors:  Donal M Keogan; Darren M Griffith
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

Review 4.  Recent advances in bioinorganic chemistry of bismuth.

Authors:  Hongyan Li; Hongzhe Sun
Journal:  Curr Opin Chem Biol       Date:  2012-02-07       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.